Sarepta price target raised to $170 from $149 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Sarepta to $170 from $149 and keeps an Overweight rating on the shares following the Q4 update. The company provided an update post the recent FDA mid-cycle meeting where no panel vote was planned and no major safety issues were identified with SRP-9001 gene therapy in Duchenne muscular dystrophy, the analyst tells investors in a research note. The firm continues to view SRP-9001 as a potentially best-in-class DMD gene therapy and now sees enhanced probability for accelerated approval.